^
    Back
    Association details:
    Biomarker:EGFR overexpression
    Cancer:Triple Negative Breast Cancer
    Drug:navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) +
    depatuxizumab mafodotin (ABT-414) (Microtubule inhibitor, EGFR-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Breast Cancer Res
    Title:

    Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

    Published date:
    11/30/2020
    Excerpt:
    The pre-clinical efficacy of combined treatments was evaluated in multiple patient-derived xenograft (PDX) models of TNBC….Treatment with navitoclax plus ABT-414 caused a significant reduction in tumor growth in five of seven PDXs and significant tumor regression in the highest EGFR-expressing PDX.
    DOI:
    10.1186/s13058-020-01374-8